Virios Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
2.830
-1.045 (-26.97%)
At close: Oct 9, 2024, 4:00 PM
2.800
-0.030 (-1.06%)
After-hours: Oct 9, 2024, 7:59 PM EDT
Company Description
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.
The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID.
The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020.
The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Contact Details
Address: 44 Milton Avenue Alpharetta, Georgia 30009 United States | |
| Phone | 866 620 8655 |
| Website | virios.com |
Stock Details
| Ticker Symbol | DWTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818844 |
Key Executives
| Name | Position |
|---|---|
| Gregory Duncan | Chief Executive Officer |
| Ralph Grosswald | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 7, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 7, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jun 20, 2024 | 8-K | Current Report |
| Jun 12, 2024 | 8-K | Current Report |
| May 20, 2024 | 424B4 | Prospectus |
| May 20, 2024 | 8-K | Current Report |
| May 17, 2024 | 424B4 | Prospectus |
| May 10, 2024 | 10-Q | Quarterly Report |